Considering also their aggressive clinical behavior, pancreatic adenocarcinomas may represent an ideal cancer type for studying new drugs targeting MTAP-deficient cancer cells in clinical trials. The gene discussed is MTAP; the disease is pancreatic adenocarcinoma.